United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,877,400 | $2,327,500 | $1,936,300 | $1,685,500 |
| % Growth | 23.6% | 20.2% | 14.9% | – |
| Cost of Goods Sold | $309,700 | $257,500 | $146,700 | $122,500 |
| Gross Profit | $2,567,700 | $2,070,000 | $1,789,600 | $1,563,000 |
| % Margin | 89.2% | 88.9% | 92.4% | 92.7% |
| R&D Expenses | $481,000 | $408,000 | $322,900 | $540,100 |
| G&A Expenses | $542,300 | $395,300 | $416,200 | $402,600 |
| SG&A Expenses | $638,600 | $477,100 | $487,000 | $467,000 |
| Sales & Mktg Exp. | $96,300 | $81,800 | $70,800 | $64,400 |
| Other Operating Expenses | $71,100 | $0 | $0 | $0 |
| Operating Expenses | $1,190,700 | $885,100 | $809,900 | $1,007,100 |
| Operating Income | $1,377,000 | $1,184,900 | $979,700 | $555,900 |
| % Margin | 47.9% | 50.9% | 50.6% | 33% |
| Other Income/Exp. Net | $162,000 | $89,400 | -$29,100 | $38,000 |
| Pre-Tax Income | $1,539,000 | $1,274,300 | $950,600 | $593,900 |
| Tax Expense | $343,900 | $289,500 | $223,300 | $118,100 |
| Net Income | $1,195,100 | $984,800 | $727,300 | $475,800 |
| % Margin | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS | 26.44 | 21.04 | 15.98 | 10.6 |
| % Growth | 25.7% | 31.7% | 50.8% | – |
| EPS Diluted | 24.64 | 19.81 | 15 | 10.06 |
| Weighted Avg Shares Out | 45,200 | 46,800 | 45,500 | 44,900 |
| Weighted Avg Shares Out Dil | 48,500 | 49,700 | 48,500 | 47,300 |
| Supplemental Information | – | – | – | – |
| Interest Income | $199,100 | $162,700 | $45,200 | $16,700 |
| Interest Expense | $42,900 | $59,300 | $32,400 | $18,600 |
| Depreciation & Amortization | $72,500 | $53,200 | $51,300 | $49,900 |
| EBITDA | $1,654,400 | $1,386,800 | $1,040,300 | $736,800 |
| % Margin | 57.5% | 59.6% | 53.7% | 43.7% |